Related Experiment Video
Updated: May 12, 2026
15:48
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
Multiple sclerosis: from molecules to treatment.
1School of Medicine, Gold Coast Campus, Griffith University, QLD 4222, Queensland, Australia. simon.broadley@griffith.edu.au.
International Journal of Molecular Sciences
|April 25, 2013
Summary
Multiple sclerosis treatments have advanced significantly due to molecular research. This progress unifies diverse scientific approaches for better disease understanding and management.
Area of Science:
- Neuroimmunology
- Molecular Medicine
- Biochemistry
Background:
- The past two decades have witnessed a paradigm shift in multiple sclerosis (MS) therapeutics.
- Investigative strategies are increasingly converging on the molecular underpinnings of MS pathogenesis.
Discussion:
- This special issue emphasizes the molecular mechanisms driving MS.
- Alignment of research methodologies facilitates a comprehensive understanding of the disease.
Key Insights:
- Molecular insights are revolutionizing multiple sclerosis treatment strategies.
- Growing consensus in research approaches accelerates therapeutic development.
Outlook:
- The current era offers unprecedented opportunities for MS research.
- Continued focus on molecular aspects promises further breakthroughs in managing MS.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...